| Literature DB >> 30591524 |
Ilaria Laudadio1, Francesca Orso2, Gianluca Azzalin3, Carlo Calabrò3, Francesco Berardinelli4, Elisa Coluzzi4, Silvia Gioiosa5, Daniela Taverna2, Antonella Sgura4, Claudia Carissimi3, Valerio Fulci3.
Abstract
Telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) constitute the core telomerase enzyme that maintains the length of telomeres. Telomere maintenance is affected in a broad range of cancer and degenerative disorders. Taking advantage of gain- and loss-of-function approaches, we show that Argonaute 2 (AGO2) promotes telomerase activity and stimulates the association between TERT and TERC AGO2 depletion results in shorter telomeres as well as in lower proliferation rates in vitro and in vivo We also demonstrate that AGO2 interacts with TERC and with a newly identified sRNA (terc-sRNA), arising from the H/ACA box of TERC Notably, terc-sRNA is sufficient to enhance telomerase activity when overexpressed. Analyses of sRNA-Seq datasets show that terc-sRNA is detected in primary human tissues and increases in tumors as compared to control tissues. Collectively, these data uncover a new layer of complexity in the regulation of telomerase activity by AGO2 and might lay the foundation for new therapeutic targets in tumors and telomere diseases.Entities:
Keywords: Argonaute; cancer; non‐coding RNA; telomerase; telomere
Year: 2018 PMID: 30591524 PMCID: PMC6362350 DOI: 10.15252/embr.201845969
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807